Daix (France), Long Island City (New York, United States), March 22, 2024
– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of steatohepatitis associated with metabolic dysfunction (MASH), or NASH, and other diseases with an unmet medical need, today announced that its management team will present the Company’s 2023 financial results on Thursday, March 28, 2024, during a webcast presentation.
Inventiva’s 2023 financial results will be published on Wednesday March 27, 2024 at 4:00 p.m. (New York), 9:00 p.m. (Paris).
A conference call
followed by a question and answer session, moderated by Frédéric Cren, Chairman and CEO and co-founder of Inventiva, Pierre Broqua, Scientific Director and co-founder of Inventiva, and Jean Volatier, Financial Administrative Director of Inventiva, will be held in English
on Thursday March 28, 2024 at 8:00 a.m. (New York), 1:00 p.m. (Paris).
The conference call and the presentation slides can be followed simultaneously at the following address:
https://edge.media-server.com/mmc/p/eh78kegs
and will also be available on the Inventiva website in the “
Investors – Financial results
“.
In order to receive the access information necessary to participate in the conference call, it is required to register in advance
via the following link:
https://register.vevent.com/register/BIca56dabf4edf46ecaaca0e735626f044
. Participants will need to use the conference access information provided in the email received at the time of registration (call-in number and access code).
The conference call and presentation will be accessible online
replay
after the event to the following address:
http://inventivapharma.com/fr/investors/resultats-financiers-presentations/
.
About Inventiva
Inventiva is a biopharmaceutical company focused on the research and development of orally administered small molecules for the treatment of patients with MASH/NASH, and other diseases with significant unmet medical needs. The Company has significant experience and expertise in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently developing a clinical candidate, has a pipeline of two preclinical programs and continues to explore additional development opportunities to expand its portfolio.
Lanifibranor, Inventiva’s most advanced drug candidate, is currently being evaluated in the pivotal Phase III NATiV3 clinical study for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease, for for which there is currently no approved treatment.
Inventiva’s portfolio also includes odiparcil, a drug candidate for the treatment of adult patients suffering from MPS type VI. As part of its decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended its clinical efforts relating to odiparcil and is reviewing all available options to optimize its development. Inventiva is also in the process of selecting a drug candidate in oncology as part of its program dedicated to the Hippo signaling pathway.
The Company has a scientific team of approximately 90 people with strong expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology as well as clinical development. Inventiva has a chemical library of approximately 240,000 molecules, approximately 60% of which are exclusive to the Company, as well as its own laboratories and equipment.
Inventiva is a company listed on compartment B of the regulated market of Euronext Paris (symbol: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).
www.inventivapharma.com
.
Contacts
Attachment
Inventiva – CP – Webcast invitation FY 2023 – FR – 03.22.2024